Increasing dose of radioactive iodine in Graves' disease with historical control

Phase 3

Completed

• Conditions: Graves' disease, remission, radioactive iodine; disease patients required radioactive iodine treatment.

• Registration Number: TCTR20220322002
• Lead Sponsor: Phrapokklao Hospital

Brief Summary

Higher dosage (20 mCi) RAI showed superior efficacy in achieving remission compared to lower dosages (10 - 15 mCi) in Graves disease treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-22
• Study Completion: 2023-06-30
• Results First Posted: 2024-04-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 219

Inclusion Criteria

1. Patiens with a diagnosis of Graves' disease in ICD10 code
2. Age 18 or older

Exclusion Criteria

1. Pregnancy or lactation
2. Received previous radioactive iodine or surgery
3. Co-existing or suspicious thyroid cancer
4. Active or severe Graves' orbitopathy
5. Hyperthyroidism from other causes such as toxic adenoma, toxic multinodular goiter or thyroiditis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Remission At 6 months after the intervention Thyroid fuction test

Secondary Outcome Measures

Name	Time	Method
Time to remission At 6 months after the intervention Thyroid function test